Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer
Start Date
4/22/2022
Completion Date
5/1/2028
Summary
This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET/CT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.
Detailed Description
PRIMARY OBJECTIVES: I. Evaluate fluorine F 18 tetrafluoroborate (18F-TFB) positron emission tomography (PET)/computed tomography (CT) imaging in patients with intermediate or high risk differentiated thyroid cancer (DTC) and compare to the current clinical standard. II. Assess the impact of 18F-TFB PET/CT on clinical management. OUTLINE: Patients receive fluorine F 18 tetrafluoroborate intravenously (IV) and undergo PET/CT scan on study.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Computed Tomography
Fluorine F 18 Tetrafluoroborate
Positron Emission Tomography
Survey Administration
Conditions
Locations
Mayo Clinic in Rochester
Rochester, Minnesota 55905
United States